CD28
T-cell-specific surface glycoprotein CD28
As of the edition of 20 October 2026, CD28 (T-cell-specific surface glycoprotein CD28, UniProt P10747) has 6 drugs tested at it and 6 companies on the list, 5 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P10747
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Solved structures
- 10
- Disease areas
- Immune system; Skin and connective tissue; Bones, joints and muscles; Infections; Urinary and reproductive; Cancer; Digestive system; Eye
- Registered trials of its drugs
- 18
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 1 |
| Stopped | 4 |
| Status not established | 1 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Lulizumab pegol | Stopped | Phase 2 | none listed |
| TGN-1412 | Went quiet | Phase 2 | none listed |
| Reltecimod | Stopped | Phase 3 | none listed |
| Acazicolcept | Stopped | Phase 2 | none listed |
| FR104 | Status not established | Phase 2 | none listed |
| SAR442257 | Stopped | Phase 1 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Undetermined | 1 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| Bristol Myers Squibb | Route A |
| Atox Bio | Route A |
| Sanofi | Route A |
The other 3 companies at CD28
In the product6 companies in all; 3 are not named here, and no score is.
See the 6 companies at CD28, ranked, with the facts behind eachRequest access. Nothing is shown until you do.